drugset / Trial / NCT07580794
First-in-human Study of HSK56630 in Healthy Subjects
Phase 1
Recruiting
40 enrolled
Haisco Pharmaceutical Group Co., Ltd.
Veritus Research Pty Ltd · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a first-in-human, single ascending dose (SAD) study in healthy adult participants. This is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and PK of HSK56630 in healthy adult participants and preliminarily evaluate the PD of HSK56630.
Timeline
- Start
- 2026-06-17
- Primary completion
- 2026-08-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK56630 | Unknown | — | Oral |
Indications
No indication recorded.